Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Apellis Pharmaceuticals Inc’s stock clocked out at $23.94, down -3.74% from its previous closing price of $24.87. In other words, the price has decreased by -$3.74 from its previous closing price. On the day, 1.88 million shares were traded. APLS stock price reached its highest trading level at $25.46 during the session, while it also had its lowest trading level at $23.69.
Ratios:
To gain a deeper understanding of APLS’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.30 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 38.52. For the most recent quarter (mrq), Quick Ratio is recorded 3.10 and its Current Ratio is at 3.54. In the meantime, Its Debt-to-Equity ratio is 1.18 whereas as Long-Term Debt/Eq ratio is at 0.93.
On October 15, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $32.
Goldman Downgraded its Neutral to Sell on September 26, 2025, while the target price for the stock was maintained at $18.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 05 ’26 when Baumal Caroline sold 3,020 shares for $25.53 per share. The transaction valued at 77,097 led to the insider holds 91,206 shares of the business.
Baumal Caroline bought 3,020 shares of APLS for $77,097 on Jan 05 ’26. On Dec 16 ’25, another insider, Watson David O., who serves as the General Counsel of the company, sold 5,000 shares for $24.49 each. As a result, the insider received 122,450 and left with 103,730 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APLS now has a Market Capitalization of 3029013760 and an Enterprise Value of 3024155648. As of this moment, Apellis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 80.63. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.98 while its Price-to-Book (P/B) ratio in mrq is 7.55. Its current Enterprise Value per Revenue stands at 2.975 whereas that against EBITDA is 36.843.
Stock Price History:
The Beta on a monthly basis for APLS is 0.25, which has changed by -0.24636364 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, APLS has reached a high of $35.57, while it has fallen to a 52-week low of $16.10. The 50-Day Moving Average of the stock is 4.31%, while the 200-Day Moving Average is calculated to be 9.24%.
Shares Statistics:
It appears that APLS traded 2.59M shares on average per day over the past three months and 2037670 shares per day over the past ten days. A total of 126.50M shares are outstanding, with a floating share count of 103.76M. Insiders hold about 17.99% of the company’s shares, while institutions hold 99.29% stake in the company. Shares short for APLS as of 1765756800 were 17247829 with a Short Ratio of 6.65, compared to 1763078400 on 16349387. Therefore, it implies a Short% of Shares Outstanding of 17247829 and a Short% of Float of 17.940001.
Earnings Estimates
Apellis Pharmaceuticals Inc (APLS) is presently subject to a detailed evaluation by 11.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.51, with high estimates of -$0.37 and low estimates of -$0.63.
Analysts are recommending an EPS of between $0.48 and $0.04 for the fiscal current year, implying an average EPS of $0.28. EPS for the following year is -$1.16, with 11.0 analysts recommending between -$0.09 and -$1.73.
Revenue Estimates
In. The current quarter, 19 analysts expect revenue to total $200.44M. It ranges from a high estimate of $232.4M to a low estimate of $184.82M. As of. The current estimate, Apellis Pharmaceuticals Inc’s year-ago sales were $212.53MFor the next quarter, 19 analysts are estimating revenue of $190.89M. There is a high estimate of $208.5M for the next quarter, whereas the lowest estimate is $174M.
A total of 20 analysts have provided revenue estimates for APLS’s current fiscal year. The highest revenue estimate was $1.05B, while the lowest revenue estimate was $988.69M, resulting in an average revenue estimate of $1.01B. In the same quarter a year ago, actual revenue was $781.37MBased on 20 analysts’ estimates, the company’s revenue will be $863.98M in the next fiscal year. The high estimate is $955M and the low estimate is $787.62M.
